- Home
- KSPI vs RPRX Comparison
KSPI vs RPRX Comparison
Compare KSPI & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KSPI
- RPRX
- Stock Information
- Founded
- KSPI 2008
- RPRX 1996
- Country
- KSPI Kazakhstan
- RPRX United States
- Employees
- KSPI N/A
- RPRX N/A
- Industry
- KSPI
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- KSPI
- RPRX Health Care
- Exchange
- KSPI Nasdaq
- RPRX Nasdaq
- Market Cap
- KSPI 15.7B
- RPRX 15.6B
- IPO Year
- KSPI 2024
- RPRX 2020
- Fundamental
- Price
- KSPI $92.52
- RPRX $35.98
- Analyst Decision
- KSPI Buy
- RPRX Strong Buy
- Analyst Count
- KSPI 3
- RPRX 3
- Target Price
- KSPI $122.00
- RPRX $45.33
- AVG Volume (30 Days)
- KSPI 365.3K
- RPRX 3.0M
- Earning Date
- KSPI 10-20-2025
- RPRX 08-06-2025
- Dividend Yield
- KSPI 1.85%
- RPRX 2.44%
- EPS Growth
- KSPI 17.03
- RPRX 54.86
- EPS
- KSPI 10.97
- RPRX 2.32
- Revenue
- KSPI $6,128,365,283.00
- RPRX $2,305,243,000.00
- Revenue This Year
- KSPI $23.67
- RPRX $28.60
- Revenue Next Year
- KSPI $20.73
- RPRX $8.07
- P/E Ratio
- KSPI $8.44
- RPRX $15.49
- Revenue Growth
- KSPI 43.08
- RPRX 3.02
- 52 Week Low
- KSPI $75.90
- RPRX $24.05
- 52 Week High
- KSPI $131.62
- RPRX $38.00
- Technical
- Relative Strength Index (RSI)
- KSPI 55.10
- RPRX 46.13
- Support Level
- KSPI $89.79
- RPRX $35.79
- Resistance Level
- KSPI $99.20
- RPRX $36.90
- Average True Range (ATR)
- KSPI 2.69
- RPRX 0.90
- MACD
- KSPI -0.31
- RPRX -0.13
- Stochastic Oscillator
- KSPI 44.88
- RPRX 8.78
About KSPI Joint Stock Company Kaspi.kz
Kaspi.kz JSC is the payment, marketplace, and Fintech ecosystem in Kazakhstan. The firm provides interconnected technologically seamless products and services that help people to pay, shop and manage their finances. Its operating segment includes the Payments Platform that connects its customers, which consist of both consumers and merchants, to facilitate cashless, digital transactions, the Marketplace Platform that connects merchants and consumers enabling merchants to increase their sales and consumers to buy a broad selection of products and services offered by a variety of merchants, and Fintech Platform that enables customers to manage their personal finances online and access consumer finance and deposit products through the Kaspi.kz Super App.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.